AAM
GALT icon

American Asset Management’s Galectin Therapeutics GALT Stock Holding History

American Asset Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-84
Closed – – 35
2015
Q3 		$0 Buy
+84
New +$198 ﹤0.01% 113
2014
Q4 		– Sell
-84
Closed – – 32
2014
Q3 		$0 Buy
+84
New +$654 ﹤0.01% 115

Other funds holding GALT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
BCCM
Blue Clay Capital Management Minneapolis, Minnesota $88.7M AUM 6.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

American Asset Management's GALT Position: Q4 2015 in Review

American Asset Management sold out of Galectin Therapeutics (GALT) in Q4 2015, closing a stake of 84 shares.

American Asset Management first reported a position in GALT in Q3 2014 and held it in 2 quarters. The position peaked at $0 in Q3 2015. 58 funds tracked by Wall St. Rank hold GALT as of Q4 2015.

  • American Asset Management reported no remaining Galectin Therapeutics position as of Q4 2015 after selling out during the quarter.
  • American Asset Management sold 84 Galectin Therapeutics shares in Q4 2015.
  • American Asset Management first reported a position in Galectin Therapeutics in Q3 2014 and held it in 2 quarters.
  • American Asset Management's Galectin Therapeutics position peaked at $0 in Q3 2015.
  • 58 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2015.

Based on American Asset Management's 13F filing for Q4 2015, filed 19 Jan 2016.